Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABR2
- Development stage
- Phase 1
- Lead developer
- Pleryon Therapeutics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
ABR2 is a novel ocular lubricating eye drop developed by Pleryon Therapeutics for the temporary relief of ocular discomfort and dryness associated with dry eye syndrome. The product is designed to supplement or stabilize the tear film, providing symptomatic relief for patients experiencing ocular dryness. ABR2 is currently being evaluated in clinical trials (e.g., NCT06341400) to assess its safety and tolerability in both single-dose and multi-dose (28-day) regimens. The development of ABR2 leverages Pleryon's focus on advanced ophthalmic formulations to address unmet needs in the management of dry eye syndrome.
Beyond the preview
Go deeper on ABR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABR2.